The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
aESTEEM 1 study. Data as observed from patients in the full analysis set. Results were consistent between ESTEEM 1 and ESTEEM 2.
OTEZLA significantly reduces pruritus severity as early as week 22
*Pruritus was measured on a 100-mm VAS. Baseline values: Placebo, 65.0 mm; OTEZLA 30 mg BID, 66.1 mm.
BID, twice daily; BL, baseline; DLQI, Dermatology Life Quality Index; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; VAS, visual analogue scale.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
